An oncolytic HSV-1 vector induces a therapeutic adaptive immune response against glioblastoma
EGFP-oHSV1 demonstrates potent antitumoral activity in an immunocompetent GBM model as a monotherapy, resulting from direct cell killing combined with the stimulation of a protective adaptive immune response. These results open the way to possible application of our strategy in clinical setting.
Authors
- Arianna Calistri (ORCID: https://orcid.org/0000-0002-6881-7936)
- Greta Forlani (ORCID: https://orcid.org/0000-0003-1987-7761)
- Stefano La Rosa (ORCID: https://orcid.org/0000-0003-1941-2403)
- Mariam Shallak
- Andrea Gatta
- Anna Maria Chiaravalli (ORCID: https://orcid.org/0000-0002-3924-2117)
- Roberto S. Accolla (ORCID: https://orcid.org/0000-0003-2493-7378)
- Alberto Reale (ORCID: https://orcid.org/0000-0003-1737-8635)
- Amruth Kaleem Basha Shaik (ORCID: https://orcid.org/0000-0001-6525-2282)
- Martina Zaccaria
- Michele Cerati
Institutions
- University of Insubria (IT)
- University of Padua (IT)
- American Association for the Surgery of Trauma (US)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12967-024-05650-5
- Citations
- 11
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 6.05